Articles related to Hematology

According to the American Institute for Cancer Research, a diet filled with a variety of vegetables, fruits, whole grains, beans, and other plant foods helps lower risk for many cancers, thanks to their bioactive compounds. Things like bergamottin. Isothiocyanates. Polyphenols. Continue reading to discover five foods that have the potential to fight cancer, including pancreatic, skin, and more.

In this Original Investigation from JAMA, the authors attempt to discover how the landscape of cancer incidences and deaths will change in the next two decades. The findings suggest marked changes in the landscape of cancer incidence and deaths by 2040, emphasizing the importance of cancer screening, early detection, and prevention to guide research, health care, and health policy efforts.

US News & World Report recently published its state healthcare rankings, based on three measures: access to healthcare, quality of care, and overall health of the population, measuring rates of obesity, smoking, suicide, mental health, and mortality for adults and infants. At the top, Hawaii was the clear winner. At the bottom, Mississippi. Where does your state measure up in the rankings?

The IRS was kind enough to move the traditional tax deadline from April 15 to Monday, May 17, granting a bit of a reprieve for getting your financial affairs in order. Many physicians choose to handle their taxes themselves despite a good CPA paying for him/herself in the deductions and tax-savings strategies that they find for you. If you decide to go this route, here are some things you should be asking.

From the pages of Oncology Times comes the latest approvals, designations, and new indications from the U.S. Food and Drug Administration (FDA) for oncology drugs. Stories include new approvals in multiple myeloma, esophageal or gastroesophageal junction (GEJ) carcinoma, non-small cell lung cancer (NSCLC), anaplastic lymphoma, and more.

The FDA’s Oncologic Drugs Advisory Committee will hold a public meeting from April 27 to 29, 2020, to reevaluate six treatments that were previously granted accelerated approval and have since reported results that failed to verify clinical benefit. The six indications to be discussed include atezolizumab (two indications), pembrolizumab (three indications), and nivolumab (one indication).